Melanoma-Associated Retinopathy: Symptoms, Diagnosis, and Care

The most common early symptom of MAR is sudden night blindness, also called nyctalopia (nick-tah-LOW-pee-ah). People with MAR often notice they can no longer see clearly in dim lighting or that they struggle to adjust when moving from a brightly lit space into a darker one.

This happens because the ON-bipolar cells targeted by MAR autoantibodies are especially important for low-light and low-contrast vision. Night blindness is typically the symptom that first prompts patients to seek an eye evaluation.

Another hallmark symptom of MAR is photopsia (foe-TOP-see-ah), the perception of flickering, shimmering, or flashing lights that have no external source. These disturbances can occur at any time of day, including in well-lit environments, and may be persistent rather than occasional.

Photopsia in MAR reflects the abnormal electrical activity of retinal cells caused by autoantibody interference. Some patients describe it as a shimmering or glowing overlay across their visual field.

As MAR progresses, side (peripheral) vision often begins to narrow. Objects off to the side become harder to detect, and the visual field constricts over time. Reduced contrast sensitivity, meaning difficulty distinguishing objects from their backgrounds, is also common.

Central vision is usually preserved in the early stages, which can make MAR feel less urgent than it actually is. However, peripheral and low-light vision can decline significantly over weeks to months without treatment.

One of the most diagnostically challenging aspects of MAR is that the retina frequently appears completely normal during a standard eye examination, particularly early in the disease. A fundus exam, which provides a direct view of the back of the eye, may reveal no visible damage.

This normal appearance can delay diagnosis because MAR does not present like a typical retinal disease. A high level of clinical suspicion is required, especially in anyone with a melanoma history who reports unexplained vision changes.

Without treatment, visual symptoms in MAR typically worsen over weeks to months. With appropriate therapy, many patients achieve stable vision over a period of years. Outcomes depend on how much retinal damage has occurred at the time of diagnosis, how well the underlying melanoma responds to treatment, and how the individual responds to immunosuppressive therapy.

Early diagnosis and prompt treatment offer the best opportunity to preserve useful vision over the long term. Patients who are evaluated at the first sign of symptoms generally fare better than those who delay seeking care.

Regular visits with a retina specialist are essential for tracking retinal function over time. ERG testing is repeated periodically to assess whether bipolar cell activity is stable, improving, or declining. Visual field testing and OCT imaging are also used at regular intervals to monitor for changes.

Oncologic follow-up continues in parallel to manage the melanoma and adjust cancer treatment as needed. Our team stays in close communication with referring oncologists to ensure coordinated and consistent care at every stage.

The primary goal of MAR treatment is to stabilize vision and slow or stop further retinal damage. While some patients do experience meaningful visual improvement, complete reversal of vision loss is not typical. Night blindness and peripheral vision changes may persist to some degree even with successful treatment.

Understanding these realities early allows patients and their care teams to make informed decisions about treatment goals and quality-of-life priorities from the very beginning.

Yes. In some patients, the visual symptoms of MAR appear before metastatic disease has been detected through routine imaging or blood work. If you have a history of melanoma and develop unexplained night blindness or flickering lights, your care team should consider whether a thorough oncologic evaluation is warranted. Treating the eye symptoms as an isolated vision problem without investigating the cancer status could delay an important diagnosis and affect overall treatment planning.

They are related but distinct conditions. Cancer-associated retinopathy (CAR) is associated with a variety of cancers, most commonly small cell lung cancer, and primarily damages photoreceptors, which are the cells that first detect light. MAR specifically occurs with melanoma and targets ON-bipolar cells through TRPM1 autoantibodies. The ERG patterns, visual symptoms, and underlying mechanisms differ meaningfully between the two, and accurate differentiation matters because it guides different treatment approaches.

Controlling the melanoma can reduce the production of the autoantibodies damaging the retina. For some patients, effective cancer treatment leads to stabilization or modest visual improvement, particularly when combined with immunosuppressive therapy directed at protecting the eye. However, retinal cells that have already been damaged may not fully recover. The earlier treatment begins, the better the chance of preserving the vision that remains rather than trying to recover what has been lost.

Checkpoint inhibitors are highly effective against metastatic melanoma, but they work by enhancing immune activity, which may also worsen the autoimmune damage to the retina in MAR. This does not mean these medications cannot be used, but it does mean that close monitoring by both your oncologist and a retina specialist is essential throughout treatment. Any worsening of vision while on these medications should prompt an urgent eye evaluation rather than a watch-and-wait approach.

Visit frequency depends on the severity of your condition and how well it is responding to treatment. During active treatment or in the early stages after diagnosis, appointments may be scheduled every few weeks to every few months. Once the condition stabilizes, intervals may lengthen, but long-term ERG and visual field monitoring typically continues indefinitely. We tailor the monitoring schedule to each individual's situation and adjust it as the condition evolves over time.

Research into MAR is ongoing, though the rarity of the condition limits large-scale clinical trials. The identification of TRPM1 as the primary autoantibody target has opened the door to more precise diagnostic approaches and may eventually lead to more targeted therapies. Intravitreal steroid implants represent a newer treatment strategy with encouraging early findings. Patients interested in clinical trials or emerging options should ask their retina specialist and oncologist whether any active studies may be suitable for their specific situation.